Indivior PLC (NASDAQ:INDV) Given Consensus Rating of “Moderate Buy” by Analysts

Indivior PLC (NASDAQ:INDV) has earned a consensus rating of “Moderate Buy” from the seven analysts that are covering the company, Marketbeat reports. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $39.3333.

Several research firms have recently weighed in on INDV. HC Wainwright upped their price target on shares of Indivior from $35.00 to $48.00 and gave the stock a “buy” rating in a report on Monday, January 12th. Zacks Research lowered Indivior from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 13th. Northland Securities set a $50.00 price target on Indivior in a research report on Tuesday, January 20th. Weiss Ratings reissued a “hold (c)” rating on shares of Indivior in a report on Wednesday, January 28th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $41.00 target price (up from $27.00) on shares of Indivior in a research note on Friday, October 31st.

Insider Activity

In other news, Director Barbara Ryan purchased 775 shares of the stock in a transaction on Monday, January 5th. The shares were acquired at an average price of $35.39 per share, for a total transaction of $27,427.25. Following the completion of the transaction, the director directly owned 1,963 shares of the company’s stock, valued at approximately $69,470.57. This trade represents a 65.24% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, Director Daniel A. Ninivaggi purchased 775 shares of the company’s stock in a transaction on Monday, January 5th. The shares were purchased at an average cost of $35.39 per share, with a total value of $27,427.25. Following the purchase, the director owned 16,923 shares of the company’s stock, valued at approximately $598,904.97. The trade was a 4.80% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last 90 days, insiders have bought 4,871 shares of company stock worth $172,385.

Hedge Funds Weigh In On Indivior

Institutional investors have recently modified their holdings of the company. Commonwealth of Pennsylvania Public School Empls Retrmt SYS bought a new stake in shares of Indivior in the 2nd quarter valued at about $855,000. Federated Hermes Inc. purchased a new position in Indivior in the 3rd quarter worth approximately $8,120,000. Pacer Advisors Inc. bought a new stake in Indivior in the third quarter valued at approximately $9,086,000. Acadian Asset Management LLC boosted its stake in shares of Indivior by 124.4% during the second quarter. Acadian Asset Management LLC now owns 1,492,272 shares of the company’s stock valued at $21,977,000 after purchasing an additional 827,230 shares during the period. Finally, Geode Capital Management LLC grew its holdings in shares of Indivior by 1,122.6% in the second quarter. Geode Capital Management LLC now owns 1,576,915 shares of the company’s stock worth $23,244,000 after purchasing an additional 1,447,939 shares during the last quarter. 60.33% of the stock is currently owned by institutional investors.

Indivior Trading Down 0.3%

INDV stock opened at $34.36 on Friday. The firm has a 50 day moving average of $34.95 and a 200-day moving average of $28.49. The firm has a market capitalization of $4.30 billion, a P/E ratio of 37.35 and a beta of 0.80. Indivior has a 12 month low of $7.62 and a 12 month high of $38.00.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.